Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia

In the last decade, long-acting injectable antipsychotics has been widely used in schizophrenia. Aripiprazole long-acting once-monthly (AOM) is the only long-acting dopamine partial agonist antipsychotic approved for schizophrenia; however, a literature search revealed no guidance on safely switchin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chih-Sung Liang, Tung-Ping Su, Ming-Hsien Hsieh, Chau-Shoun Lee, Joseph Kuo, Nan-Ying Chiu, Po-See Chen, Yung-Chieh Yen, Ya-Mei Bai
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	schizophrenia long-acting injectable antipsychotic aripiprazole atypical antipsychotic expert consensus guidance Medicine R
Acceso en línea:	https://doaj.org/article/1fcb18cc1408495db83c294b2b1b7b3a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1fcb18cc1408495db83c294b2b1b7b3a
record_format	dspace
spelling	oai:doaj.org-article:1fcb18cc1408495db83c294b2b1b7b3a2021-11-25T18:07:57ZTaiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia10.3390/jpm111111982075-4426https://doaj.org/article/1fcb18cc1408495db83c294b2b1b7b3a2021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1198https://doaj.org/toc/2075-4426In the last decade, long-acting injectable antipsychotics has been widely used in schizophrenia. Aripiprazole long-acting once-monthly (AOM) is the only long-acting dopamine partial agonist antipsychotic approved for schizophrenia; however, a literature search revealed no guidance on safely switching from oral and long-acting injectable antipsychotics to AOM. This study aimed to develop recommendations of AOM use based on existing data and expert consensus. A committee of 30 experts in psychopharmacology from major hospitals across Taiwan was invited. A modified Delphi method was conducted, consisting of two rounds of questionnaires, literature review, three rounds of face-to-face discussion meeting, and two rounds of anonymous voting. The consensus recommendations were developed based on existing data, clinical experiences, and consensus opinions, with 80% agreement among panel members required for final adoption. The panel developed nine consensus statements of switching to AOM for both acute and stable schizophrenia patients receiving oral or long-acting injectable atypical antipsychotics. Recommendations regarding dose adjustment of oral medication and pregnancy/breastfeeding were also included. The nine consensus recommendations provide a guidance on safely switching to AOM. Substantial gaps in knowledge, and more research is necessary.Chih-Sung LiangTung-Ping SuMing-Hsien HsiehChau-Shoun LeeJoseph KuoNan-Ying ChiuPo-See ChenYung-Chieh YenYa-Mei BaiMDPI AGarticleschizophrenialong-acting injectable antipsychoticaripiprazoleatypical antipsychoticexpert consensusguidanceMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1198, p 1198 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenia long-acting injectable antipsychotic aripiprazole atypical antipsychotic expert consensus guidance Medicine R
spellingShingle	schizophrenia long-acting injectable antipsychotic aripiprazole atypical antipsychotic expert consensus guidance Medicine R Chih-Sung Liang Tung-Ping Su Ming-Hsien Hsieh Chau-Shoun Lee Joseph Kuo Nan-Ying Chiu Po-See Chen Yung-Chieh Yen Ya-Mei Bai Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
description	In the last decade, long-acting injectable antipsychotics has been widely used in schizophrenia. Aripiprazole long-acting once-monthly (AOM) is the only long-acting dopamine partial agonist antipsychotic approved for schizophrenia; however, a literature search revealed no guidance on safely switching from oral and long-acting injectable antipsychotics to AOM. This study aimed to develop recommendations of AOM use based on existing data and expert consensus. A committee of 30 experts in psychopharmacology from major hospitals across Taiwan was invited. A modified Delphi method was conducted, consisting of two rounds of questionnaires, literature review, three rounds of face-to-face discussion meeting, and two rounds of anonymous voting. The consensus recommendations were developed based on existing data, clinical experiences, and consensus opinions, with 80% agreement among panel members required for final adoption. The panel developed nine consensus statements of switching to AOM for both acute and stable schizophrenia patients receiving oral or long-acting injectable atypical antipsychotics. Recommendations regarding dose adjustment of oral medication and pregnancy/breastfeeding were also included. The nine consensus recommendations provide a guidance on safely switching to AOM. Substantial gaps in knowledge, and more research is necessary.
format	article
author	Chih-Sung Liang Tung-Ping Su Ming-Hsien Hsieh Chau-Shoun Lee Joseph Kuo Nan-Ying Chiu Po-See Chen Yung-Chieh Yen Ya-Mei Bai
author_facet	Chih-Sung Liang Tung-Ping Su Ming-Hsien Hsieh Chau-Shoun Lee Joseph Kuo Nan-Ying Chiu Po-See Chen Yung-Chieh Yen Ya-Mei Bai
author_sort	Chih-Sung Liang
title	Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
title_short	Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
title_full	Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
title_fullStr	Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
title_full_unstemmed	Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
title_sort	taiwan expert consensus recommendations for switching to aripiprazole long-acting once-monthly in patients with schizophrenia
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1fcb18cc1408495db83c294b2b1b7b3a
work_keys_str_mv	AT chihsungliang taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia AT tungpingsu taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia AT minghsienhsieh taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia AT chaushounlee taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia AT josephkuo taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia AT nanyingchiu taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia AT poseechen taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia AT yungchiehyen taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia AT yameibai taiwanexpertconsensusrecommendationsforswitchingtoaripiprazolelongactingoncemonthlyinpatientswithschizophrenia
_version_	1718411546976059392

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia

Ejemplares similares